Aurora Cannabis Snags MedReleaf in $3.2 Billion Deal

James West
|

Midas Letter Chart (ACB:TSX,LEAF:TSX)

Aurora Cannabis Inc (TSE:ACB) (OTCQB:ACBFF) (FRA:21P) and MedReleaf Corp (TSE:LEAF) (OTCMKTS:MEDFF) (FRA:MEW) announced the biggest merger yet in the Canadian Cannabis sector in an all stock transaction valued at $3.2 billion.

The purchase price implies a premium of thirty-four percent over the average last 20 sessions share price, giving MedReleaf shareholders a major win at $29.45 a share.

“This is transformational transaction that brings together two pioneering cannabis comapnies, ” said Aurora CEO Terry Booth.

Neil Closner, MeReleaf’s CEO said “By combining with Aurora, an integrated producer with an exceptionally strong track record for execution, and deep domestic and international distribution capabilities, we will be ideally positioned to set the global standard for our industry at a pace that will be difficult to match.”

Listen to Aurora Chief Corporate Officer Cam Battley discuss the merger with MedReleaf on Midas Letter LIVE!.

James West

James West

Editor and Publisher

I employ a Capital Efficiency Model that dictates money should never be exposed for longer than is absolutely necessary to the possibility of being lost. Thus, I routinely sell half my position when a stock doubles from my entry price, and I sell stocks that lose 20%, unless there are...
More Info...

[email protected] | |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!